Genetic Information

Gene & Transcript Details

Gene
PTEN
Transcript
NM_000314.8 MANE Select
Total Exons
Reference Sequence
NC_000010.10
Alternative Transcripts
IDStatusDetails
NM_000314.7 RefSeq Select 8514 nt | 845–2056
NM_000314.5 Alternative 8719 nt | 1032–2243
NM_000314.4 Alternative 5572 nt | 1032–2243
NM_000314.3 Alternative 3416 nt | 1032–2243
NM_000314.6 Alternative 8718 nt | 1032–2243
NM_000314.8 MANE Select 8515 nt | 846–2057

Variant Details

HGVS Notation
NM_000314.8:c.70G>A
Protein Change
D24N
Location
Exon 1 (Exon 1 of )
1
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Pathogenic
1 publications
Publications List
PMID: 21194675

The p.D24N pathogenic mutation (also known as c.70G>A), located in coding exon 1 of the PTEN gene, results from a G to A substitution at nucleotide position 70. The aspartic acid at codon 24 is replaced by asparagine, an amino acid with highly similar properties. This variant was reported in individuals with features consistent with PTEN hamartoma tumor syndrome in at least one individual, it was determined to be de novo (external communication). In a massively parallel functional assay using a humanized yeast model, lipid phosphatase activity for this variant was functionally deficient (Mighell TL et al. Am J Hum Genet, 2018 May;102:943-955).This missense alteration is located in a region that has a low rate of benign missense variation (Lek M et al. Nature. 2016 Aug 18;536(7616):285-91; DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Firth H.V. et al. 2009. Am.J.Hum.Genet. 84, 524-533 (DOI: dx.doi.org/10/1016/j.ajhg.2009.03.010)). This amino acid position is well conserved in available vertebrate species. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation.

PMID: 17213812

This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 24 of the PTEN protein (p.Asp24Asn). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of PTEN-related conditions (internal data). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 185200). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PTEN protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect PTEN function (PMID: 17213812). This variant disrupts the p.Asp24 amino acid residue in PTEN. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 24778394, 29706633; internal data). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

Clinical Statement

"This variant has been reported in ClinVar as Pathogenic (3 clinical laboratories)."

COSMIC Somatic Evidence

Open
COSMIC ID
COSM5079
Recurrence
8 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene PTEN.

Functional Studies & Therapeutic Relevance

Functional Summary

The PTEN D24N variant has been functionally characterized and demonstrates a damaging effect. Although it retains phosphatase activity, it exhibits aberrant nuclear localization and fails to inhibit Akt phosphorylation, cell proliferation, and transformation in cell culture, indicating a loss of function.

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.02 -85 bp
- Donor Loss (DL) 0.0 85 bp
+ Acceptor Gain (AG) 0.0 -270 bp
+ Donor Gain (DG) 0.01 9 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PVS1

PVS1 (Not Applied)

According to VCEP guidelines: "Very Strong Use PTEN PVS1 decision tree. Modification Type: Disease-specific." The variant is a missense change (D24N), not a predicted loss-of-function. Therefore, PVS1 is not applied.

PS1

PS1 (Not Applied)

According to VCEP guidelines: "Strong Same amino acid change as a previously established pathogenic variant regardless of nucleotide change OR different variant at same nucleotide position as a pathogenic splicing variant..." There is no previously established pathogenic D24 change or splicing variant at this position. Therefore, PS1 is not applied.

PS2

PS2 (Not Applied)

According to VCEP guidelines: De novo occurrence criteria for PS2. No confirmed de novo observations are reported. Therefore, PS2 is not applied.

PS3

PS3 (Moderate)

According to PTEN Pre-processing finding: "Moderate Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. Phosphatase activity ≤ -1.11 per Mighell et al. 2018, PMID: 29706350." The PTEN D24N variant has a functional score of -1.5498 (< -1.11), demonstrating damaging effect. Therefore, PS3 is applied at Moderate strength.

PS4

PS4 (Not Applied)

According to VCEP guidelines: Probands specificity score criteria for PS4. No case-control or proband specificity data are available. Therefore, PS4 is not applied.

PM1

PM1 (Not Applied)

According to VCEP guidelines: "Moderate Located in a mutational hot spot and/or critical and well-established functional domain: residues 90-94, 123-130, 166-168." D24 is outside these defined regions. Therefore, PM1 is not applied.

PM2

PM2 (Supporting)

According to VCEP guidelines: "Supporting Absent in population Databases present at <0.00001 (0.001%) allele frequency in gnomAD or another large sequenced population..." The variant is absent from gnomAD and other large population databases. Therefore, PM2 is applied at Supporting strength.

PM3

PM3 (Not Applied)

According to VCEP guidelines: PM3 pertains to variants in trans with a pathogenic variant in recessive disease. PTEN-associated disorders are dominant and no trans observations with another PTEN variant are reported. Therefore, PM3 is not applied.

PM4

PM4 (Not Applied)

According to VCEP guidelines: PM4 applies to in-frame insertions/deletions or protein length changes. This variant is a missense substitution. Therefore, PM4 is not applied.

PM5

PM5 (Not Applied)

According to VCEP guidelines: PM5 is for a different missense change at the same residue with established pathogenicity. No other pathogenic missense substitutions at residue D24 have been reported. Therefore, PM5 is not applied.

PM6

PM6 (Not Applied)

According to VCEP guidelines: PM6 pertains to assumed de novo occurrences. No de novo data are provided. Therefore, PM6 is not applied.

PP1

PP1 (Not Applied)

According to VCEP guidelines: PP1 requires segregation data. No family segregation data are available. Therefore, PP1 is not applied.

PP2

PP2 (Not Applied)

According to standard ACMG: "Supporting Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease." PTEN has both missense and truncating pathogenic variants and a moderate rate of benign missense. Therefore, PP2 is not applied.

PP3

PP3 (Not Applied)

According to VCEP guidelines: "Supporting Multiple lines of computational evidence support a deleterious effect (REVEL > 0.7 for missense)." In silico results are mixed and do not meet concordance for pathogenic. Therefore, PP3 is not applied.

PP4

PP4 (Not Applied)

According to standard ACMG: PP4 requires highly specific phenotype data. No phenotype information is provided. Therefore, PP4 is not applied.

PP5

PP5 (Supporting)

According to standard ACMG: "Supporting Reputable source recently reports variant as pathogenic, but the evidence is not available for independent evaluation." ClinVar reports this variant as Pathogenic by three clinical laboratories. Therefore, PP5 is applied at Supporting strength.

BA1

BA1 (Not Applied)

According to VCEP guidelines: "Stand Alone gnomAD Filtering allele frequency >0.00056 (0.056%)." The variant is absent in gnomAD, below this threshold. Therefore, BA1 is not applied.

BS1

BS1 (Not Applied)

According to VCEP guidelines: "Strong Allele frequency from 0.000043 up to 0.00056." The variant is absent in gnomAD, below this range. Therefore, BS1 is not applied.

BS2

BS2 (Not Applied)

According to VCEP guidelines: BS2 requires observations of homozygosity in healthy individuals. None are reported. Therefore, BS2 is not applied.

BS3

BS3 (Not Applied)

According to VCEP guidelines: BS3 requires well-established functional studies showing no damaging effect. Functional assays demonstrate damaging effect. Therefore, BS3 is not applied.

BS4

BS4 (Not Applied)

According to VCEP guidelines: BS4 requires lack of segregation in multiple affected family members. No such data are available. Therefore, BS4 is not applied.

BP1

BP1 (Not Applied)

According to standard ACMG: "Supporting Missense variant in a gene where only truncating variants cause disease." PTEN has known pathogenic missense variants. Therefore, BP1 is not applied.

BP2

BP2 (Not Applied)

According to VCEP guidelines: BP2 requires observations in trans or in cis with other pathogenic PTEN variants. None are reported. Therefore, BP2 is not applied.

BP3

BP3 (Not Applied)

According to standard ACMG: BP3 applies to in-frame indels in repetitive regions. This is a missense variant. Therefore, BP3 is not applied.

BP4

BP4 (Supporting)

According to VCEP guidelines: "Supporting Multiple lines of computational evidence suggest no impact on gene or gene product. Missense variants: REVEL scores < 0.5." In silico predictions are mixed with several benign scores and SpliceAI shows no splicing impact. Therefore, BP4 is applied at Supporting strength.

BP5

BP5 (Not Applied)

According to VCEP guidelines: BP5 requires an alternate molecular basis for disease in the same case. No such alternate basis is reported. Therefore, BP5 is not applied.

BP6

BP6 (Not Applied)

According to standard ACMG: "Supporting A variant reported as benign by a reputable source without available evidence." No such benign reports exist. Therefore, BP6 is not applied.

BP7

BP7 (Not Applied)

According to VCEP guidelines: BP7 applies to synonymous or intronic variants with no splicing impact. This is a missense variant. Therefore, BP7 is not applied.